Načítá se...
Linagliptin inhibits lipopolysaccharide-induced inflammation in human U937 monocytes
BACKGROUND: Atherosclerosis and inflammation are more common in patients with diabetes than in patients without diabetes, and atherosclerosis progression contributes to inflammation. Therefore, anti-inflammatory therapy is important for the prognosis of patients with diabetes. Linagliptin is the onl...
Uloženo v:
| Vydáno v: | Inflamm Regen |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6100723/ https://ncbi.nlm.nih.gov/pubmed/30151063 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s41232-018-0071-z |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|